Design of experiment-driven stability-indicating RP-HPLC method for the determination of tofacitinib in nanoparticles and skin matrix

Design of experiment-driven stability-indicating RP-HPLC method for the determination of tofacitinib in nanoparticles and skin matrix

Abstract Background Tofacitinib—an oral JAK inhibitor—has been recently approved by US FDA to treat moderate to severe RA. The delivery of tofacitinib to specific inflammation site at joint via topical route using nanoformulations helps in managing the potential adverse effects. The objective is to...

Full description

Bibliographic Details
Main Authors: Srividya Gorantla, Ranendra N. Saha, Gautam Singhvi
Format: Article
Language:English
Published: SpringerOpen 2021-08-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Dermatokinetic study
Factorial design
HPLC
Nanoparticles
Tofacitinib
Online Access:https://doi.org/10.1186/s43094-021-00325-0

Similar Items

Similar Items